SST and neoplasm: The fourth approved indication for SST analogs in patients with NETs is their use to target cytotoxic radiolabeled SST analogs to the tumor in patients with advanced NETs, as an anti-tumor therapy (called PRRT for peptide receptor radionuclide therapy) (124–127).